Xencor (XNCR) Current Assets (2013 - 2026)
Xencor (XNCR) posted quarterly Current Assets of $482.9 million for Q1 2026, down 7.37% year-over-year from $521.3 million in Q1 2025, and down 19.5% quarter-over-quarter from $599.8 million in Q4 2025.
Xencor (XNCR) Current Assets (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Current Assets for 14 consecutive years, with $482.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 7.37% year-over-year to $482.9 million; the TTM figure through Mar 2026 stood at $482.9 million (down 7.37% YoY), while the FY2025 annual figure was $599.8 million, up 3.85% from the prior year.
- Current Assets retreated to $482.9 million in Q1 2026 per XNCR's latest filing, from $599.8 million in the prior quarter.
- Across five years, Current Assets topped out at $675.3 million in Q4 2022 and bottomed at $482.9 million in Q1 2026.
- Historically, Current Assets has averaged $577.2 million across 5 years, with a median of $577.6 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets jumped 102.65% — and 2023, when it fell 14.49%.
- Xencor's Current Assets stood at $675.3 million in 2022, then declined by 5.88% to $635.6 million in 2023, then declined by 9.13% to $577.6 million in 2024, then rose by 3.85% to $599.8 million in 2025, then retreated by 19.5% to $482.9 million in 2026.
- Business Quant data shows XNCR's Current Assets at $482.9 million in Q1 2026, $599.8 million in Q4 2025, and $518.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 523.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 523.21 Mn |
| Mar 31, 2026 | 482.86 Mn |
| Dec 31, 2025 | 599.82 Mn |
| Sep 30, 2025 | 518.44 Mn |
| Jun 30, 2025 | 513.15 Mn |
| Mar 31, 2025 | 521.27 Mn |
| Dec 31, 2024 | 577.60 Mn |
| Sep 30, 2024 | 589.60 Mn |
| Jun 30, 2024 | 568.92 Mn |
| Mar 31, 2024 | 574.85 Mn |
| Dec 31, 2023 | 635.60 Mn |
| Sep 30, 2023 | 571.18 Mn |
| Jun 30, 2023 | 593.56 Mn |
| Mar 31, 2023 | 629.98 Mn |
| Dec 31, 2022 | 675.34 Mn |
| Sep 30, 2022 | 668.00 Mn |
| Jun 30, 2022 | 585.94 Mn |
| Mar 31, 2022 | 505.97 Mn |
| Dec 31, 2021 | 424.37 Mn |
| Sep 30, 2021 | 329.63 Mn |